Posts

Posted on

FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection

FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection

NEWARK, Calif.–(BUSINESS WIRE)–
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has deferred a decision on the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar (frown) lines.

In a communication received on November 24, 2020, the FDA reiterated that an inspection of the company’s manufacturing facility is required as part of the BLA approval process. The Agency was unable to conduct a required inspection of the company’s Northern California manufacturing facility due to the Agency’s travel restrictions associated with the COVID-19 pandemic. Revance confirmed with the FDA that their communication was not a Complete Response Letter.

Though the company’s BLA is still under review, the FDA did not indicate there are any other review issues at this time, beyond the on-site inspection. The FDA stated they are actively working to define an approach for scheduling outstanding inspections, once safe travel may resume and based on public health need and other factors.

“We appreciate FDA’s engagement on the Chemistry, Manufacturing and Controls (CMC), non-clinical, clinical and labeling sections of our BLA, particularly given the unique and unprecedented situation we are in as a result of the COVID-19 pandemic. We look forward to continued interaction with the Agency and remain ready to support FDA’s pre-approval inspection as soon as possible. We are fortunate that we manufacture our product at a single location in the U.S., which should put us at an advantage compared to international manufacturing locations once travel resumes,” said Mark J. Foley, President and Chief Executive Officer. “As stated in our third quarter earnings, with the addition of the RHA® Collection of dermal fillers and acquisition of the HintMD fintech platform earlier this year, we believe the company is in an excellent position, both commercially and financially, to weather a change to the timing of this potential approval.”

DaxibotulinumtoxinA for Injection is an investigational agent that combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. In the first quarter of 2020, Revance announced that the BLA for DaxibotulinumtoxinA for Injection had been accepted for review by the FDA and the company had been given a Prescription Drug User Fee Act (PDUFA) target action date of November 25, 2020. The submission was based on results from the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar (frown) lines, including the SAKURA 1, 2 and 3 Phase 3 clinical studies.

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in two therapeutic indications – cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.

Forward-Looking Statement: Revance Therapeutics

Any statements in this press release that are not statements of historical fact, including statements related to statements about our ability to obtain, and the timing relating to, regulatory approval with respect to DaxibotulinumtoxinA for Injection in glabellar lines and the expected PDUFA date; the inspection by the FDA of our manufacturing facility in connection with the BLA approval process, including the timing and outcome of and factors impacting the inspection; our financial performance; our commercial potential; development of a biosimilar to BOTOX®; and statements about our business strategy, timeline and other goals, plans and prospects, including our commercialization plans, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances, or achievements reflected in the forward-looking statements will ever be achieved or occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate, but are not limited to: the results and timing of our regulatory approvals; delays in the approval of our BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines due to COVID-19-related policies and travel restrictions currently in place at the FDA; the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, end user demand for our products, commercialization efforts, business operations, clinical trials and other aspects of our business; our ability to manufacture supplies for our product candidates and to acquire supplies of the RHA® Collection of dermal fillers; the uncertain clinical development process; the risk that clinical trials may not have an effective design or generate positive results; the applicability of clinical study results to actual outcomes; our ability to obtain regulatory approval of our drug product candidates; whether the HintMD acquisition and Teoxane agreement will provide the anticipated economic and other benefits; the rate and degree of commercial acceptance and the market, size and growth potential of the RHA® Collection of dermal fillers, the HintMD payments platform and our drug product candidates, if approved; our ability to successfully commercialize the RHA® Collection of dermal fillers, the HintMD payments platform and our drug product candidates, if approved, and the timing and cost of commercialization activities; our ability to develop sales and marketing capabilities; the status of commercial collaborations; our ability to obtain funding for our operations; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and our financial performance, including future revenue, expenses and capital requirements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled “Risks Factors” on our Form 10-Q filed with the SEC on November 9, 2020. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

[email protected]

or

General Media

Goodfuse

Jenifer Slaw, 347-971-0906

[email protected]

or

Trade Media

Nadine Tosk, 504-453-8344

[email protected]

Investors

Revance Therapeutics, Inc.:

Jeanie Herbert, 714-325-3584

[email protected]

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology FDA Other Health Health Pharmaceutical

MEDIA:

Bank of America 2020 Leveraged Finance Conference

Date:

Monday, November 30, 2020

Time:

12:45 p.m. Eastern Time

Imperial Capital 17th Annual Virtual Security Investor Conference

Date:

Wednesday, December 2, 2020

Time:

1:00 p.m. Eastern Time

Presentations will be available via live webcast and archived on Vivint’s investor relations website at http://investors.vivint.com/.

About the Company

Vivint is a leading smart home company in North America. Vivint delivers an integrated smart home system with in-home consultation, professional installation and support delivered by its Smart Home Pros, as well as 24/7 customer care and monitoring. Dedicated to redefining the home experience with intelligent products and services, Vivint serves approximately 1.7 million customers throughout the U.S. and Canada. For more information, visit https://www.vivint.com.

Source: Vivint Smart Home, Inc.

VVNT-E

Investor Relations Contact:

Nate Stubbs

VP, Investor Relations

[email protected]

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Technology Construction & Property Security Other Technology Software Networks Hardware Data Management Consumer Electronics Residential Building & Real Estate

MEDIA:

Logo
Logo
Posted on

Cerebain Biotech Announces PKG, Inc. to Become Key Manufacturer for ClearMask™ and Xometry

Cerebain Biotech Announces PKG, Inc. to Become Key Manufacturer for ClearMask™ and Xometry

COSTA MESA, Calif.–(BUSINESS WIRE)–
Cerebain Biotech Corp. (OTC: CBBT), today announced that PKG, Inc. is to become the key manufacturer for ClearMask, LLC and Xometry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005429/en/

See the person, not the mask. The first fully transparent, FDA-cleared mask produced in the United States is made possible through a manufacturing partnership between ClearMask LLC, Xometry, and PKG Inc. (Photo: Business Wire)

See the person, not the mask. The first fully transparent, FDA-cleared mask produced in the United States is made possible through a manufacturing partnership between ClearMask LLC, Xometry, and PKG Inc. (Photo: Business Wire)

ClearMask™ is the world’s first FDA-cleared, fully transparent surgical mask suitable for hospitals, clinics, schools, retail, hospitality, and other settings. The mask is optimized for maximum clarity and comfort and meets applicable ASTM Level 3 requirements for fluid resistance and flammability, which offers a high level of protection for medical use in environments such as operating rooms.

“In this disheartening time as the world fights against the COVID-19 pandemic, the ClearMask™ helps protect while bringing much-needed relief through a reassuring smile and familiar face among fear and confusion and suffering. In addition to blocking particles or droplets with its fully transparent, anti-fog plastic barrier, the ClearMask™ helps improve visual communication, which may help avoid costly errors and adverse outcomes. Transparent communication during the customer experience can be critical in establishing rapport and earning trust while assuring safety as a priority,” announced ClearMask in its press release.

To meet the rigorous controls necessary for FDA-cleared products, ClearMask LLC and Xometry, the largest marketplace for On-Demand manufacturing, partnered with PKG Inc., an ISO 13485-certified facility, to manufacture the FDA-cleared version of the ClearMask™. PKG will provide valuable experience in building FDA-approved products, enabling mass production while achieving rigorous oversight and high quality.

This November, PKG Inc. officially kick-started a new production floor designed to meet the mass production of the FDA-cleared ClearMask™, which has been in high demand.

Over the next few weeks, PKG Inc. intends to fully transition company ownership to Cerebain Biotech Corporation in an acquisition that began in the middle of this year. Upon completion, under the Cerebain Biotech umbrella, PKG Inc. will continue its support in mass-producing large volumes of the FDA-cleared ClearMask™. Almir Garibovic stated “We are proud to help ClearMask fight against the pandemic with a smile on our face that everyone can see. All of us are looking forward to successfully providing innovative accessibility and protection to a diverse population.”

If you would like to order the FDA-cleared ClearMask™, visit: https://buy.theclearmask.com/.

About Cerebain Biotech Corp.

Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebookto learn more.

About ClearMask™

ClearMask™, LLC is an American-based medical supply company that focuses on improving communication while making connections more human. Its products may help reduce errors and increase satisfaction by facilitating visual communication for all. For more information, please visit www.theclearmask.com.

About Xometry

Xometry is the largest marketplace for custom manufacturing, connecting customers with optimal manufacturing solutions through proprietary AI algorithms. Xometry provides on-demand manufacturing and industrial supply materials to a diverse customer base, ranging from startups to Fortune 100 companies, including BMW, Dell Technologies, General Electric, Bosch, and NASA. Our nationwide network of thousands of supplier manufacturing facilities enables us to maintain consistently fast lead times while offering a broad array of capabilities, including CNC machining, 3D printing, sheet metal fabrication, injection molding, and urethane casting. Additionally, Xometry offers its supplier network an array of financing solutions to help improve cash flow and achieve better growth and efficiency. Learn more about Xometry at www.xometry.com or on Twitter at @xometry.

About PKG

PKG, Inc. was established in 1989 and is a privately held corporation based in Meridian, ID. PKG, Inc. specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps raise your company to the next level by leveraging our engineering and technology integration skills across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides our customers with all of their product development and manufacturing needs. Besides our expertise in system-level devices and human-machine interfaces, PKG also offers incubation and acceleration services for startup businesses and entrepreneurs. For more information visit, www.pkguis.com.

Forward Looking Statements

This news release contains certain “forward- looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

Investors:

Mr. Alan Klitenic

Cerebain Biotech Corp.

888.430.2221

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: FDA Manufacturing Other Health Managed Care General Health Medical Devices Infectious Diseases Hospitals Other Manufacturing Science Biotechnology Other Science Health Research Medical Supplies

MEDIA:

Photo
Photo
(Photo: Business Wire)
Photo
Photo
See the person, not the mask. The first fully transparent, FDA-cleared mask produced in the United States is made possible through a manufacturing partnership between ClearMask LLC, Xometry, and PKG Inc. (Photo: Business Wire)
Posted on

Boxlight Announces Director of Strategic Funding and Grants

Boxlight Announces Director of Strategic Funding and Grants

LAWRENCEVILLE, Ga.–(BUSINESS WIRE)–
Boxlight Corporation (Nasdaq: BOXL), a leading provider of interactive technology solutions, today announced that Dr. Don Gemeinhardt has joined Boxlight as Director of Strategic Funding and Grants.

Gemeinhardt will be working to locate funding opportunities available to schools and districts for education technology, STEM solutions and training needs. School Districts generally lack expertise and time to conduct grant research, and often are unaware grants may be available to fund items such as professional development and technology.

“Having seen the breadth of the Boxlight solutions and how they benefit teachers and students, I knew I wanted to help districts find funding to bring these wonderful solutions to our schools,” says Dr. Gemeinhardt.

Grants may be available from the DOE at the Federal and State levels in addition to funding from the CARES Act as it relates to Covid-19 challenges of education and safety in hybrid and remote teaching environments. Additionally, grants may be available to fund research to assist Boxlight and partners in focused R&D efforts to address current challenges in education.

“I am thrilled to add someone of Dr. Gemeinhardt’s stature to our Boxlight team,” says Dan Deem, Boxlight VP of Sales, Platforms and Services. “He brings many years of experience in helping schools find money for critical programs. Now our districts can benefit from his knowledge and experience to uncover grants to help them pay for much needed education technology, STEM programs and professional development.”

Gemeinhardt is a grant and proposal development subject matter expert, having worked with various companies involved with education, compliance training and student, faculty and police officer development. In addition to his position at Boxlight, he is an Adjunct Professor teaching in Education, History, Business and Law Enforcement, and formerly a Director at the Research Triangle Institute. He is also a retired Colonel (USAF) where he previously worked in Law Enforcement, Intelligence and Educational and Training areas for many years.

About Boxlight Corporation

Boxlight Corporation (Nasdaq: BOXL) is a leading provider of interactive technology solutions under its award-winning brands Clevertouch® and Mimio®. The Company aims to improve engagement and communication in diverse business and education environments. Boxlight develops, sells, and services its integrated solution suite including interactive displays, collaboration software, supporting accessories and professional services. For more information about the Boxlight story, visit http://www.boxlight.com.

Forward-Looking Statements

This press release may contain information about Boxlight’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements because of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to maintain and grow its business, variability of operating results, its development and introduction of new products and services, marketing and other business development initiatives, competition in the industry, etc. Boxlight encourages you to review other factors that may affect its future results in Boxlight’s filings with the Securities and Exchange Commission.

Media Relations

Sunshine Nance

+1 360-464-2119 x254

[email protected]

Investor Relations

Michael Pope

+1 360-464-4478

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Primary/Secondary Education Technology Audio/Video Software Internet

MEDIA:

Posted on

FirstEnergy Ohio Utilities’ Electric Security Plan ESP‑IV Auction: Information Session for Prospective Bidders on Wednesday, December 2, 2020

FirstEnergy Ohio Utilities’ Electric Security Plan ESP‑IV Auction: Information Session for Prospective Bidders on Wednesday, December 2, 2020

BOSTON–(BUSINESS WIRE)–CRA International, Inc. (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that an auction process will be conducted for FirstEnergy Corp.’s (NYSE: FE) Ohio utilities to procure full requirements service for their Standard Service Offer customers. The auction process will lead up to the auction scheduled for January 26, 2021.

The bidding process will use a descending-price clock auction format. The auction will be managed by the Auction Manager, CRA International, Inc. The auction is being conducted pursuant to the FirstEnergy Ohio Utilities’ Electric Security Plan (ESP‑IV) as approved by the Public Utilities Commission of Ohio (PUCO). This is the twelfth auction in the series of ESP‑IV auctions.

The Information Session for prospective bidders for the January auction is scheduled for Wednesday, December 2, 2020. Instructions on how to join the Webcast session are available on the Auction Information Website at www.firstenergycbp.com. Part 1 Applications from prospective bidders will be accepted starting December 3 and are due no later than December 18. For successful Part 1 applicants, the submission window for the Part 2 Application process will be January 4 through January 14.

The product in the January 26 auction is a 12-month contract (delivery period June 2021 through May 2022).

Additional information about the auction process can be found at the Information Website at www.firstenergycbp.com.

About CRA International, Inc. and its Auctions & Competitive Bidding Practice

CRA is a global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world and celebrated its 50th anniversary in 2015. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook. CRA’s Auctions & Competitive Bidding Practice offers businesses, governments, bidders, and other market participants extensive experience in auction and market design, implementation, monitoring, and participation. More information about CRA’s Auctions & Competitive Bidding Practice is available at www.auctions.crai.com.

Media Relations

Charles River Associates

[email protected]

617-425-3620

Nick Manganaro

Sharon Merrill Associates, Inc.

[email protected]

617-542-5300

 

KEYWORDS: Massachusetts Ohio United States North America

INDUSTRY KEYWORDS: Professional Services Other Energy Other Professional Services Utilities Legal Energy Consulting

MEDIA:

Logo
Logo
Posted on

Hologic to Webcast Presentation at Upcoming Virtual Investor Conference

Hologic to Webcast Presentation at Upcoming Virtual Investor Conference

MARLBOROUGH, Mass.–(BUSINESS WIRE)–
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 p.m. Eastern Time.

The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcast will be available for 30 days following the event.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com

SOURCE: Hologic, Inc.

Paula Izidoro

Senior Investor Relations Specialist

(858) 410-8904

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Health Medical Devices

MEDIA:

Logo
Logo
Posted on

Verint December Events Focus on the Power of AI and Digital Transformation to Elevate Customer Experience

Verint December Events Focus on the Power of AI and Digital Transformation to Elevate Customer Experience

MELVILLE, N.Y.–(BUSINESS WIRE)–Verint® Systems Inc. (Nasdaq: VRNT), The Customer Engagement Company™, today announced the December speaker line-up that explores how companies can leverage artificial intelligence to drive innovation into their digital transformation efforts to better balance customer experience with operational efficiency.

MSDO Fall Speakers Series

Virtual Conference

December 1, Noon ET

Join Verint’s Mike Biros, vice president, and David Moody, general manager, Engagement Management, as they discuss “Digital Transformation in the Era of COVID-19.” The pandemic has accelerated the digital transformation of government and impacted the way services are delivered to citizens. Attendees will learn about best practices for digital transformation that will allow citizens to receive a consistent, positive experience—no matter what channels they use to communicate.

2021 Contact Center Innovations: A Preview

DestinationCRM Virtual Conference

December 2, 2 p.m. ET

What are the most valuable contact center innovations in 2020? Where are executives deriving the most return-on-investment or realizing operational efficiencies? Technological innovations in the contact center are driving better business outcomes and creating stronger competitive advantages. Artificial intelligence, robotic process automation, speech analytics, workforce optimization, and more are all part of the discussion. Join Verint’s Kelly Koelliker, director, content marketing, for this roundtable to learn how to maximize the productivity of work-from-home employees and understand how managers can gain the visibility they need across the workforce.

The Virtual AI Summit NY

Virtual Conference

December 9-10

On December 9, Verint’s Tracy Malingo, general manager, Verint Intelligent Self-Service, delivers the keynote on the Implement Stage: “The Road to AI Success and ROI in the Enterprise is Paved in Your Data” at 12:15 p.m. ET. Attendees will learn how to unlock the power of conversational data to propel success while continuously improving, convert AI from small projects to strategic initiatives, drive intelligence across the enterprise and identify the characteristics to consider when hiring AI talent for business.

Verint’s Heather Richards, vice president, product strategy and go-to-market, Knowledge Management, is participating in a panel discussion at 3:15 p.m. ET titled “Driving Innovation Through Uncertainty – How Are Tech Leaders Accelerating Digital Transformation Projects Sustainably, Inclusively, and at Scale?” The panel will discuss how to maintain an organization’s long-term vision and digitally transform in a sustainable way.

On December 10, Verint’s Daniel Ziv, vice president, speech and text analytics, global product strategy, is participating in a panel discussion at 3:30 p.m. ET titled “AI-driven CX Solutions Reconnect Brands with Consumers in a Post-pandemic World.” Attendees will learn about how the pandemic has changed the way consumers engage with brands and how they perceive AI-driven CX solutions.

About Verint Systems Inc.

Verint® (Nasdaq: VRNT) is a global leader in Actionable Intelligence® solutions with a focus on customer engagement optimization and cyber intelligence. Today, over 10,000 organizations in more than 180 countries—including over 85 percent of the Fortune 100—count on intelligence from Verint solutions to make more informed, effective and timely decisions. Learn more about how we’re creating A Smarter World with Actionable Intelligence®, www.verint.com.

This press release contains “forward-looking statements,” including statements regarding expectations, predictions, views, opportunities, plans, strategies, beliefs, and statements of similar effect relating to Verint Systems Inc. These forward-looking statements are not guarantees of future performance and they are based on management’s expectations that involve a number of risks, uncertainties and assumptions, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. For a detailed discussion of these risk factors, see our Annual Report on Form 10-K for the fiscal year ended January 31, 2020, our Quarterly Report on Form 10-Q for the quarter ended July 31, 2020, and other filings we make with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release and, except as required by law, Verint assumes no obligation to update or revise them or to provide reasons why actual results may differ.

VERINT, ACTIONABLE INTELLIGENCE, THE CUSTOMER ENGAGEMENT COMPANY, CUSTOMER ENGAGEMENT SOLUTIONS, CYBER INTELLIGENCE SOLUTIONS, GI2, FIRSTMILE, OMNIX, WEBINT, LUMINAR, RELIANT, VANTAGE, STAR-GATE, TERROGENCE, SENSECY, and VIGIA are trademarks or registered trademarks of Verint Systems Inc. or its subsidiaries. Verint and other parties may also have trademark rights in other terms used herein.

Media Relations:

Amy Curry

Verint Systems Inc.

[email protected]

Investor Relations:

Alan Roden

Verint Systems Inc.

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Internet Security Hardware Technology Software

MEDIA:

Logo
Logo
Posted on

Hall of Fame Resort & Entertainment Company Reveals Details of Hall Of Trivia on HQ App

Hall of Fame Resort & Entertainment Company Reveals Details of Hall Of Trivia on HQ App

Show airs every Thursday night at 8 p.m. EST before NFL’s Thursday night game

Participants have opportunities to win cash and other prizes

CANTON, Ohio–(BUSINESS WIRE)–
Hall of Fame Resort & Entertainment Company (“HOFV” or the “Company”) (NASDAQ: HOFV, HOFVW), the only resort, entertainment and media company centered around the power of professional football and owner of the Hall of Fame Village powered by Johnson Controls, today shared details on Hall Of Trivia, its live weekly football, fantasy and sports-themed trivia and entertainment show airing exclusively on the HQ Trivia app every Thursday at 8 p.m. EST. The show, which is co-produced by HQ Trivia and The Hall Of Fantasy League (“HOFL”), HOFV’s fantasy sports brand, is hosted by sports broadcaster Jeff Eisenband and features appearances from NFL legends, as well as prominent sports and fantasy personalities.

Hall Of Trivia allows the most passionate sports fans to participate in a fun and interactive competition directly from their mobile and tablet devices. Each episode consists of topical football and fantasy-themed questions, providing participants with the opportunity to test their knowledge of the current NFL season and the game’s storied history. Participants who answer all questions correctly share in a standard cash prize of $2,500. A special Thanksgiving edition of the show will feature a cash prize of $10,000.

“We are thrilled to advance the Hall Of Fantasy League brand with the HQ Trivia show, which offers our community the opportunity to participate in the excitement of the current season,” said Mat Sposta, Principal with HOFL. “Our goal for the show each week will be to entertain fans and leverage key Pro Football Hall of Fame talent while garnering attention for the HOFL as we look toward the 2021 NFL season. We look forward to announcing more details on the structure of the HOFL and its rules in the coming months.”

In addition to the standard trivia format, the show offers fans the chance to take part in a season-long “Start/Sit Fantasy Pick ‘Em Pool” contest in which participants are provided with two or more NFL players in a given week and must select the player they think will score more fantasy points. Tracked throughout the course of the season, participants who accumulate the most correct selections by the end of the competition will share a cash prize of $10,000.

While the Hall Of Trivia format is primarily focused around its trivia portion, the show also contains various segments devoted to providing analysis and commentary around all of the week’s football and fantasy action. Notably, the show has featured Hall of Famers Curtis Martin and Anthony Muñoz, and plans to continue incorporating more football legends into its programming throughout the course of the season.

“Trivia is a huge part of the experience for so many sports fans,” said Eisenband. “Whether it’s arguing at the bar or texting friends in a group thread, sports enthusiasts are always debating history and facts. With Hall Of Trivia, we are challenging football fans to see how much they really know about the game they love. And considering that so many people are stuck at home looking for some joy in their lives during the pandemic , we hope we can bring them a few minutes of fun – and maybe some extra cash – on Thursday nights!”

The HOFL is the first community-backed national fantasy league. Launching with 10 regionally based franchises in key U.S. markets, HOFL teams will be managed by a dedicated front office of fantasy experts and former NFL players. Participation in the league will come in the form of staking which will allow the public to financially back individual teams, become team stakeholders, and gain access to exclusive content, communications, and team governance features. The HOFL’s inaugural draft is expected to take place in summer of 2021 and its first season will commence alongside the 2021-22 NFL season. For more information visit www.thehofl.com.

For more information on Hall Of Trivia and the rules of the show, download the HQ app on iOS or the Google Play Store.

About the Hall of Fame Resort & Entertainment Company

The Hall of Fame Resort & Entertainment Company (NASDAQ: HOFV, HOFVW) is a resort and entertainment company leveraging the power and popularity of professional football and its legendary players in partnership with the Pro Football Hall of Fame. Headquartered in Canton, Ohio, the Hall of Fame Resort & Entertainment Company is the owner of the Hall of Fame Village powered by Johnson Controls, a multi-use sports, entertainment and media destination centered around the Pro Football Hall of Fame’s campus. Additional information on the Company can be found at www.HOFREco.com.

Forward-Looking Statements

Certain statements made herein are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words and phrases such as “opportunity,” “future,” “will,” “goal,” and “look forward” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include the inability to recognize the anticipated benefits of the business combination; costs related to the business combination; the inability to obtain or maintain the listing of the Company’s shares on Nasdaq; the Company’s ability to manage growth; the Company’s ability to execute its business plan and meet its projections; potential litigation involving the Company; changes in applicable laws or regulations; general economic and market conditions impacting demand for the Company’s products and services, and in particular economic and market conditions in the resort and entertainment industry; the potential adverse effects of the ongoing global coronavirus (COVID-19) pandemic on capital markets, general economic conditions, unemployment and the Company’s liquidity, operations and personnel, as well as those risks and uncertainties discussed from time to time in our reports and other public filings with the SEC. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media/Investor Contacts:

For Hall of Fame Resort & Entertainment Company

Media Inquiries: [email protected]

Investor Inquiries: [email protected]

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Men Football Other Travel Entertainment Online Lodging Mobile Entertainment Destinations Travel Consumer General Entertainment Sports Vacation Women

MEDIA:

Logo
Logo
Posted on

Stingray Launches Free, Ad-supported TV Channels with 11 Partners Worldwide; Potential Audience Reach Grows by Over 200 M

  • Qello Concerts by Stingray, Stingray Karaoke, Stingray Classica, Stingray DJAZZ, Stingray Naturescape and Stingray Music
  • Comcast Xfinity, DistroTV, Freebie TV, Freecast, MX Player, Peacock, Redbox, Samsung TV Plus, STIRR, STV and Vizio Watch Free add Stingray services to their content offering

MONTREAL, Nov. 25, 2020 (GLOBE NEWSWIRE) — Stingray Group Inc. (TSX: RAY. A; RAY.B), a leading music, media, and technology company, today announced the launch of free, ad-supported TV channels with eleven major OTT providers: Comcast Xfinity (US), DistroTV (US), Freebie TV (US), Freecast (US), MX Player (US and India), Peacock (US), Redbox (US), Samsung TV Plus (UK and Germany), STIRR (US), STV (UK) and Vizio Watch Free (US). These distribution agreements grow Stingray’s potential reach by over 200 million viewers.

With this announcement, Stingray confirms new partnerships with Freebie TV, Peacock, Redbox and STV, and solidifies existing relationships with Comcast Xfinity, DistroTV, Freecast, MX Player, Samsung TV Plus, STIRR and Vizio Watch Free. Stingray’s reach continues to increase at an exponential rate.

Stingray’s free ad-supported TV channels (FAST channels) offer audiences a way to access music content at no extra cost through existing streaming subscriptions. Like other free streaming services, Stingray’s content does not require additional subscriptions since it is fully supported by ads. Now, more than ever, Stingray’s music offering will reach an even wider audience looking for quality entertainment.

“What attracts the world’s biggest entertainment content providers to Stingray’s music services is our expert curation and adaptability to many platforms as technologies and audience needs evolve,” said Eric Boyko, President, Co-founder, and CEO of Stingray. “I am thrilled to launch our free, ad-supported TV channels with new and existing partners to drive organic revenues and connect with an even bigger audience. With these new distribution agreements, we have grown our potential worldwide reach by over 200 million viewers.”

FAST
C
hannel
s
highlights

Qello Concerts by Stingray features concert-films and award-winning music documentaries from the biggest and most influential artists, bands, and musicians. The channel is carried by DistroTV, Freebie TV, Freecast, MX Player, Samsung TV Plus (UK, Germany) and STV.

Stingray Karaoke includes all the top songs to sing along to from golden oldies to today’s hits. The channel is carried by Freebie TV, Freecast, MX Player, Samsung TV Plus (UK, Germany) and Vizio Watch Free.

Stingray Classica features breathtaking excerpts of orchestral performances, operas, and ballets including the grandest, most popular classical musical productions filmed around the world. The channel is carried by DistroTV, Freebie TV, Freecast and MX Player.

Stingray DJAZZ features the world of jazz without limits or boundaries with a unique selection of rare documentaries, intimate portraits, behind-the-scene footage, and exclusive interviews. The channel is carried by DistroTV, Freebie TV, Freecast and STIRR.

Stingray Naturescape
/NatureVision offers an escape to a world of stunning nature scenes, all set to peaceful soundtracks. The channel is carried by Comcast Xfinity, DistroTV, Freebie TV, Freecast, MX Player and Peacock.

Stingray Music offers audio channels curated by expert programmers in all the most popular genres including rock, pop, country, hip-hop, and Latin. The service is carried by Freebie TV, Redbox and Vizio Watch Free.

A
bout Stingray
Montreal-based Stingray Group Inc. (TSX: RAY.A; RAY.B) is a leading music, media, and technology company with over 1,200 employees worldwide. Stingray is a premium provider of curated direct-to-consumer and B2B services, including audio television channels, more than 100 radio stations, SVOD content, 4K UHD television channels, karaoke products, digital signage, in-store music, and music apps, which have been downloaded over 150 million times. Stingray reaches 400 million subscribers (or users) in 156 countries. For more information: www.stingray.com.

For more information, please contact:

Mathieu Péloquin
Senior Vice-President, Marketing and Communications
Stingray
[email protected]
1 514 664-1244, ext 2362

 



Posted on

Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split

East Setauket, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT)(“Lixte” or the “Company”), today announced the pricing of its underwritten public offering of 1,200,000 units of securities at an offering price of $4.75 per unit. Each unit is immediately separable into one share of common stock and one warrant to purchase one share of common stock and will be issued separately. The warrants underlying the units are immediately exercisable for one share of common stock at an exercise price of $5.70 and expire 5 years from the date of issuance.

The Company’s common stock and warrants will begin trading on the Nasdaq Capital Market on November 25, 2020, under the symbols “LIXT” and “LIXTW,” respectively. In connection with the offering, the Company effectuated a reverse split of its issued and outstanding common stock at a ratio of 1-for-6. The reverse stock split became effective at 4:00 p.m., Eastern Time, on Thursday, November 19, 2020. The share numbers and pricing information in this release are adjusted to reflect the impact of the reverse stock split.

The Company has granted the underwriters a 45-day option to purchase up to 180,000 additional shares of the Company’s common stock and/or up to 180,000 additional warrants to purchase shares of the Company’s common stock, or any combination thereof, to cover overallotments, if any. The offering is expected to close on or about November 30, 2020, subject to customary closing conditions.

The Company expects to receive gross proceeds of $5.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses and before any exercise of the underwriters’ overallotment option. The Company intends to use the net proceeds to fund its planned clinical trials, manufacturing its product candidate, maintain and extend its patent portfolio, retention of contract research organizations, development of a form of its primary compound, LB-100 for oral administration, and for working capital and other general corporate purposes.

WestPark Capital, Inc. and WallachBeth Capital, LLC are acting as the joint book-running managers for the offering.

This offering is being made pursuant to an effective registration statement on Form S-1 (No. 333-248588) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on November 24, 2020. A final prospectus describing the terms of the proposed offering will be filed with the SEC and may be obtained, when available, via the SEC’s website at www.sec.gov or from: WestPark Capital, Inc. – Attention: Jason Stern, 1900 Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077 or by Email: [email protected] or by telephone at (310) 203-2919.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Their product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that they believe have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Additional information about Lixte Biotechnology Holdings, Inc. is available at www.lixte.com.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as “intend,” anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company’s filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

Lixte Contact:
[email protected]
(631) 830-7092